



# OBSTETRIC HEMORRHAGE DATA FORM

**Goal:** Increase the percentage of patients accurately identified and managed for obstetric hemorrhage per unit protocol to support timely intervention and improved outcomes.

**Instructions:** Using this form, abstract **up to 10** Stage 2\* postpartum hemorrhage cases and **up to 5** Stage 3\* or 4\* cases, for patients **who delivered** at your hospital.

\*View back for hemorrhage stage definitions

**STUDY ID:** \_\_\_\_\_

<b>Discharge Month</b> _____ <b>Year</b> _____ <b>Sat/Sun/Holiday discharge</b> <input type="checkbox"/> Yes <input type="checkbox"/> No <b>Age</b> _____	<b>Ethnicity</b> <input type="checkbox"/> Hispanic <input type="checkbox"/> Non-Hispanic <input type="checkbox"/> Declined to answer <input type="checkbox"/> Unknown	<b>Pref. Language</b> <input type="checkbox"/> English <input type="checkbox"/> Spanish <input type="checkbox"/> Haitian Creole <input type="checkbox"/> Other _____ <input type="checkbox"/> Unknown	<b>Insurance</b> (check all that apply) <input type="checkbox"/> Medicaid/Med plans <input type="checkbox"/> Private <input type="checkbox"/> Self-pay <input type="checkbox"/> Other _____ <input type="checkbox"/> Unknown	<b>Delivery type:</b> <input type="checkbox"/> Vaginal <input type="checkbox"/> Scheduled C/S <input type="checkbox"/> Unplanned non-emerg. C/S <input type="checkbox"/> Emergency C/S
	<b>Race</b> (check all that apply) <input type="checkbox"/> Asian <input type="checkbox"/> Black <input type="checkbox"/> White <input type="checkbox"/> Other _____ <input type="checkbox"/> Declined to answer <input type="checkbox"/> Unknown			
<b>GA at delivery</b> _____ complete weeks <b>Hemoglobin at admission</b> _____ g/dL	<b>OB Hemorrhage Stage:</b> <input type="checkbox"/> 2 <input type="checkbox"/> 3 <input type="checkbox"/> 4	<b>Time when OB hemorrhage started:</b> <input type="checkbox"/> Antepartum <input type="checkbox"/> Intrapartum <input type="checkbox"/> Postpartum	<b>Dx related to OB hemorrhage</b> (check all that apply) <input type="checkbox"/> Uterine Atony <input type="checkbox"/> Coagulopathy <input type="checkbox"/> Lacerations <input type="checkbox"/> Other _____ <input type="checkbox"/> Retained products <input type="checkbox"/> Abnormal placentation (e.g. accreta)	

## OB Hemorrhage Identification & Management

OB Hemorrhage Risk Assessment documented: (check all that apply)	<input type="checkbox"/> On admission to L&D <input type="checkbox"/> Pre-Birth <input type="checkbox"/> On admission to postpartum
Documented blood loss	_____ ml
Was a quantitative <b>and</b> cumulative technique used to measure blood loss (QBL)?	<input type="checkbox"/> Yes <input type="checkbox"/> No
↳ If yes, please confirm that <b>cumulative</b> blood loss is documented in the patient's chart (not just birth QBL)	<input type="checkbox"/> Yes – cumulative & birth QBL <input type="checkbox"/> No – just birth QBL <input type="checkbox"/> Neither are documented
Received active management of the third stage of labor per unit protocol	<input type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/> N/A (cesarean)
# of documented hand off reports tracking cumulative blood loss	_____

## Adverse Maternal Outcome (check all that apply):

- Transfusion of ≥ 4 units of blood products
- DIC
- ARDS
- Pulmonary edema
- Renal failure
- Cardiac ischemic event
- Sepsis
- Placental abruption
- Ventilation
- Oliguria
- AFE
- ICU admission
- Liver failure
- Other \_\_\_\_\_
- None

## Adverse Neonatal Outcome:

- NICU/SCN admission
- IUFD
- Other \_\_\_\_\_
- None
- Unknown

## Clinical Debrief/Case Reviews

	Yes	No	N/A
Did the <b>physician and RN debrief</b> this case for improvement opportunities?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
If an <b>SMM case</b> , was an interdisciplinary case review referral made?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

Meds & Interventions (check all given)	After hemorrhage onset, select the order medications were given	Contraindicated?
<input type="checkbox"/> Oxytocin	<input type="checkbox"/> First <input type="checkbox"/> Second <input type="checkbox"/> Other	
<input type="checkbox"/> Methergine	<input type="checkbox"/> First <input type="checkbox"/> Second <input type="checkbox"/> Other	<input type="checkbox"/>
<input type="checkbox"/> Carboprost (Hemabate)	<input type="checkbox"/> First <input type="checkbox"/> Second <input type="checkbox"/> Other	<input type="checkbox"/>
<input type="checkbox"/> Misoprostol	<input type="checkbox"/> First <input type="checkbox"/> Second <input type="checkbox"/> Other	<input type="checkbox"/>
<input type="checkbox"/> Tranexamic acid (TXA)	Time from OB hemorrhage onset to first TXA dose: <input type="checkbox"/> less than 3 hours <input type="checkbox"/> 3 hours or more	
<input type="checkbox"/> Devices	<input type="checkbox"/> Intrauterine balloon tamponade <input type="checkbox"/> Intrauterine vacuum <input type="checkbox"/> Other _____	
<input type="checkbox"/> Surgical (check all that apply)	<input type="checkbox"/> Uterine artery ligation <input type="checkbox"/> Unplanned hysterectomy <input type="checkbox"/> Planned hysterectomy <input type="checkbox"/> Other _____	
<input type="checkbox"/> Massive Transfusion Protocol Initiated		
<input type="checkbox"/> Blood products given <b>during</b> acute OB hemorrhage		

## DISCHARGE MANAGEMENT

	Yes	No
Were verbal & written postpartum warning signs given?	<input type="checkbox"/>	<input type="checkbox"/>
Was patient verbally briefed and given a written summary of the OB hemorrhage event before discharge?	<input type="checkbox"/>	<input type="checkbox"/>
Breastfeeding/pumping at discharge?	<input type="checkbox"/>	<input type="checkbox"/>
Was a Postpartum Discharge Assessment (vital signs and response) conducted just prior to discharge?	<input type="checkbox"/>	<input type="checkbox"/>
Timing of scheduled follow-up appointments (check all that apply)	<input type="checkbox"/> within 7 days <input type="checkbox"/> 8-14 days <input type="checkbox"/> 15-21 days <input type="checkbox"/> >21 days <input type="checkbox"/> Pt. instructed/not scheduled	



# OBSTETRIC HEMORRHAGE DATA FORM

**Inclusion Criteria:** Include patients who **delivered** at your hospitals **with blood loss of  $\geq 1,000$  mL (Stage 2+ obstetric hemorrhage)**.

**Exclusion Criteria:** Exclude patients whose pregnancy ends prior to 20 weeks, ectopic pregnancies, and those with gestational trophoblastic disease.

## Monthly Data Collection Instructions:

- Abstract **up to 10** Stage 2\* ( $\geq 1,000$  mL blood loss) postpartum hemorrhage (PPH) cases and **up to 5** Stage 3\* (1,500 mL blood loss) or Stage 4\* (cardiovascular collapse) cases (maximum of 15 cases total).
- Use the first eligible cases identified each month, based on the patient's discharge date (do not randomize).
- Submit only cases for patients who delivered at your hospital.
- If fewer than the maximum number of cases occur, submit all available cases.

## Definitions

**Study ID:** Assign a unique number to each case, starting from 001 and continuing sequentially.

**Age:** Record the mother's age in completed years

**Pref. Language:** the patient's primary or most comfortable language for healthcare communication.

**\*OB Hemorrhage Stage:** Categorized according to [AWHONN staging criteria](#), with Stage 2 defined as cumulative blood loss  $\geq 1,000$  mL, Stage 3 as  $\geq 1,500$  mL, and Stage 4 indicating cardiovascular collapse; Staging should escalate based on clinical signs, regardless of blood volume, if the patient shows signs of hemodynamic instability.

**Blood Loss** should be tracked from the time of birth (prior to placental delivery) through the immediate postpartum period, typically the first 2 hours. If bleeding is excessive or prolonged, QBL should continue until bleeding is controlled and the patient is stable. While all postpartum patients should be monitored for hemorrhage throughout their stay, routine QBL is not required beyond the immediate postpartum period unless bleeding is ongoing. For significant blood loss prior to placental delivery (e.g., abruption or previa), teams should include that loss in the total QBL to support accurate clinical interpretation. **If cumulative QBL is available, report that value for "Documented Blood Loss"; otherwise, report the best available estimate documented.**

**Devices for intrauterine balloon tamponade:** Bakri ballon, BT-Cath, Sengstaken-Blakemore tube, Rusch balloon

**Devices for intrauterine contraction via vacuum:** Jada system

**Physician and Nurse Debrief:** quick, structured review after an event (e.g., OB hemorrhage) to summarize actions, identify successes and barriers, and pinpoint opportunities for rapid improvement. Use a standardized form, e.g. [AWHONN debrief form here](#).

**Patient debrief:** a structured conversation where the physician and nurse share with the patient the details of the OB hemorrhage event, including any complications, treatment, and follow-up care. Patients should receive a written summary with the details of the event – [form here](#).

**SMM – Severe Maternal Morbidity:** see definitions – and code list in the [AIM website here](#) or reach out to the FPQC data team.

**Postpartum Discharge Assessment:** take the patient's vital signs just prior to discharge and take action if values are abnormal – [see here](#).

**Timing of scheduled follow-up appointments:** Patient's follow-up appointments should be scheduled prior to discharge. Note how many days after discharge the appointments are scheduled. If not scheduled and the patient was instructed to schedule after discharge, choose 'Pt. instructed/not scheduled.'